Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Klaus P Hoeflich

Showing results (31-40 of 61) with videos related to

Pageof 7
Sort By:
Bioorganic & Medicinal Chemistry Letters|June 28, 2016
Synthesis and evaluation of a series of 4-azaindole-containing p21-activated kinase-1 inhibitorsWendy Lee, James J Crawford, Ignacio Aliagas, et al.
Cancer Research|March 12, 2009
Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppressionKlaus P Hoeflich, Sylvia Herter, Janet Tien, et al.
Cancer Research|January 21, 2006
Oncogenic BRAF is required for tumor growth and maintenance in melanoma modelsKlaus P Hoeflich, Daniel C Gray, Michael T Eby, et al.
ACS Medicinal Chemistry Letters|June 24, 2015
Leveraging the Pre-DFG Residue Thr-406 To Obtain High Kinase Selectivity in an Aminopyrazole-Type PAK1 Inhibitor SeriesJoachim Rudolph, Ignacio Aliagas, James J Crawford, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2009
Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumabEvelyn Yao, Wei Zhou, Si Tuen Lee-Hoeflich, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 9, 2012
Preclinical disposition of GDC-0973 and prospective and retrospective analysis of human dose and efficacy predictionsEdna F Choo, Marcia Belvin, Jason Boggs, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 2, 2009
In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer modelsKlaus P Hoeflich, Carol O'Brien, Zachary Boyd, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 13, 2011
Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cellsChristy C Ong, Adrian M Jubb, Peter M Haverty, et al.
Cancer Research|September 18, 2012
p21-Activated kinase 1 is required for efficient tumor formation and progression in a Ras-mediated skin cancer modelHoi Yee Chow, Adrian M Jubb, Jennifer N Koch, et al.
Oncotarget|April 27, 2017
Multiplexed gene expression profiling identifies the FGFR4 pathway as a novel biomarker in intrahepatic cholangiocarcinomaChanghoon Yoo, Jihoon Kang, Deokhoon Kim, et al.
Pageof 7

Showing results (31-40 of 61) with videos related to

Sort By:
Pageof 7
Bioorganic & Medicinal Chemistry Letters|June 28, 2016
Synthesis and evaluation of a series of 4-azaindole-containing p21-activated kinase-1 inhibitorsWendy Lee, James J Crawford, Ignacio Aliagas, et al.
Cancer Research|March 12, 2009
Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppressionKlaus P Hoeflich, Sylvia Herter, Janet Tien, et al.
Cancer Research|January 21, 2006
Oncogenic BRAF is required for tumor growth and maintenance in melanoma modelsKlaus P Hoeflich, Daniel C Gray, Michael T Eby, et al.
ACS Medicinal Chemistry Letters|June 24, 2015
Leveraging the Pre-DFG Residue Thr-406 To Obtain High Kinase Selectivity in an Aminopyrazole-Type PAK1 Inhibitor SeriesJoachim Rudolph, Ignacio Aliagas, James J Crawford, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2009
Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumabEvelyn Yao, Wei Zhou, Si Tuen Lee-Hoeflich, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 9, 2012
Preclinical disposition of GDC-0973 and prospective and retrospective analysis of human dose and efficacy predictionsEdna F Choo, Marcia Belvin, Jason Boggs, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 2, 2009
In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer modelsKlaus P Hoeflich, Carol O'Brien, Zachary Boyd, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 13, 2011
Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cellsChristy C Ong, Adrian M Jubb, Peter M Haverty, et al.
Cancer Research|September 18, 2012
p21-Activated kinase 1 is required for efficient tumor formation and progression in a Ras-mediated skin cancer modelHoi Yee Chow, Adrian M Jubb, Jennifer N Koch, et al.
Oncotarget|April 27, 2017
Multiplexed gene expression profiling identifies the FGFR4 pathway as a novel biomarker in intrahepatic cholangiocarcinomaChanghoon Yoo, Jihoon Kang, Deokhoon Kim, et al.
Pageof 7